#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction to Tissue Engineering Scaffolds and Bottom-Up Fabrication
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract[1]	new[1]	_	_
1-3	16-18	to	abstract[1]	new[1]	_	_
1-4	19-25	Tissue	abstract[1]|object|object[4]|abstract[5]	new[1]|new|new[4]|new[5]	coref|coref|coref|coref|coref|coref|coref|coref|coref	3-17|8-21[0_4]|8-21[76_5]|3-17|8-21[0_4]|8-21[76_5]|3-17|8-21[0_4]|8-21[76_5]
1-5	26-37	Engineering	abstract[1]|abstract|object[4]|abstract[5]	new[1]|new|new[4]|new[5]	coref	8-1[71_0]
1-6	38-47	Scaffolds	abstract[1]|object[4]|abstract[5]	new[1]|new[4]|new[5]	_	_
1-7	48-51	and	abstract[1]|abstract[5]	new[1]|new[5]	_	_
1-8	52-61	Bottom-Up	abstract[1]|abstract[5]|abstract|abstract[7]	new[1]|new[5]|new|new[7]	coref|coref	12-4[0_7]|12-4[0_7]
1-9	62-73	Fabrication	abstract[1]|abstract[5]|abstract[7]	new[1]|new[5]|new[7]	_	_

#Text=Traumas , diseases and population ageing are major reasons for damage and failure of human body tissues and organs , which require medical treatments for their restoration or replacement .
2-1	74-81	Traumas	abstract	new	_	_
2-2	82-83	,	_	_	_	_
2-3	84-92	diseases	abstract	new	_	_
2-4	93-96	and	_	_	_	_
2-5	97-107	population	abstract|abstract[11]	new|new[11]	coref|coref	2-8[12_11]|2-8[12_11]
2-6	108-114	ageing	abstract[11]	new[11]	_	_
2-7	115-118	are	_	_	_	_
2-8	119-124	major	abstract[12]	giv[12]	coref	7-2[63_12]
2-9	125-132	reasons	abstract[12]	giv[12]	_	_
2-10	133-136	for	abstract[12]	giv[12]	_	_
2-11	137-143	damage	abstract[12]|abstract	giv[12]|new	_	_
2-12	144-147	and	abstract[12]	giv[12]	_	_
2-13	148-155	failure	abstract[12]|event[14]	giv[12]|new[14]	_	_
2-14	156-158	of	abstract[12]|event[14]	giv[12]|new[14]	_	_
2-15	159-164	human	abstract[12]|event[14]|object[16]	giv[12]|new[14]|new[16]	coref	6-33[62_16]
2-16	165-169	body	abstract[12]|event[14]|object|object[16]	giv[12]|new[14]|new|new[16]	coref	3-4
2-17	170-177	tissues	abstract[12]|event[14]|object[16]	giv[12]|new[14]|new[16]	_	_
2-18	178-181	and	abstract[12]|event[14]	giv[12]|new[14]	_	_
2-19	182-188	organs	abstract[12]|event[14]|object	giv[12]|new[14]|new	coref	7-13
2-20	189-190	,	_	_	_	_
2-21	191-196	which	_	_	_	_
2-22	197-204	require	_	_	_	_
2-23	205-212	medical	abstract[18]	new[18]	ana	2-26[0_18]
2-24	213-223	treatments	abstract[18]	new[18]	_	_
2-25	224-227	for	_	_	_	_
2-26	228-233	their	abstract|event[20]	giv|new[20]	_	_
2-27	234-245	restoration	event[20]	new[20]	_	_
2-28	246-248	or	_	_	_	_
2-29	249-260	replacement	abstract	new	_	_
2-30	261-262	.	_	_	_	_

#Text=Despite the intrinsic body capability of repairing small injuries given sufficient time , to date , tissue growth in large ( centimeter-size ) defects requires complex , expensive and patient-painful autografts , allografts or xenografts .
3-1	263-270	Despite	_	_	_	_
3-2	271-274	the	abstract[23]	new[23]	_	_
3-3	275-284	intrinsic	abstract[23]	new[23]	_	_
3-4	285-289	body	organization|abstract[23]	giv|new[23]	coref	10-10
3-5	290-300	capability	abstract[23]	new[23]	_	_
3-6	301-303	of	_	_	_	_
3-7	304-313	repairing	_	_	_	_
3-8	314-319	small	abstract[24]	new[24]	_	_
3-9	320-328	injuries	abstract[24]	new[24]	_	_
3-10	329-334	given	_	_	_	_
3-11	335-345	sufficient	time[25]	new[25]	_	_
3-12	346-350	time	time[25]	new[25]	_	_
3-13	351-352	,	_	_	_	_
3-14	353-355	to	_	_	_	_
3-15	356-360	date	time	new	_	_
3-16	361-362	,	_	_	_	_
3-17	363-369	tissue	object|abstract[28]	giv|new[28]	coref|coref|coref|coref	6-17[58_0]|10-29[0_28]|6-17[58_0]|10-29[0_28]
3-18	370-376	growth	abstract[28]	new[28]	_	_
3-19	377-379	in	abstract[28]	new[28]	_	_
3-20	380-385	large	abstract[28]	new[28]	_	_
3-21	386-387	(	_	_	_	_
3-22	388-403	centimeter-size	abstract	new	_	_
3-23	404-405	)	_	_	_	_
3-24	406-413	defects	abstract	new	_	_
3-25	414-422	requires	_	_	_	_
3-26	423-430	complex	abstract[31]	new[31]	_	_
3-27	431-432	,	abstract[31]	new[31]	_	_
3-28	433-442	expensive	abstract[31]	new[31]	_	_
3-29	443-446	and	abstract[31]	new[31]	_	_
3-30	447-462	patient-painful	abstract[31]	new[31]	_	_
3-31	463-473	autografts	abstract[31]	new[31]	_	_
3-32	474-475	,	_	_	_	_
3-33	476-486	allografts	object	new	_	_
3-34	487-489	or	_	_	_	_
3-35	490-500	xenografts	abstract	new	_	_
3-36	501-502	.	_	_	_	_

#Text=In the case of bone , autograft and allograft implantation produces the best clinical results , but it requires secondary surgery and has a limited supply .
4-1	503-505	In	_	_	_	_
4-2	506-509	the	abstract[34]	new[34]	ana	4-18[0_34]
4-3	510-514	case	abstract[34]	new[34]	_	_
4-4	515-517	of	abstract[34]	new[34]	_	_
4-5	518-522	bone	abstract[34]|object	new[34]|new	_	_
4-6	523-524	,	_	_	_	_
4-7	525-534	autograft	event	new	_	_
4-8	535-538	and	_	_	_	_
4-9	539-548	allograft	object|event[38]	new|new[38]	coref|coref	5-20[0_38]|5-20[0_38]
4-10	549-561	implantation	event[38]	new[38]	_	_
4-11	562-570	produces	_	_	_	_
4-12	571-574	the	abstract[39]	new[39]	coref	5-19[50_39]
4-13	575-579	best	abstract[39]	new[39]	_	_
4-14	580-588	clinical	abstract[39]	new[39]	_	_
4-15	589-596	results	abstract[39]	new[39]	_	_
4-16	597-598	,	_	_	_	_
4-17	599-602	but	_	_	_	_
4-18	603-605	it	abstract	giv	_	_
4-19	606-614	requires	_	_	_	_
4-20	615-624	secondary	event[41]	new[41]	coref	5-15[48_41]
4-21	625-632	surgery	event[41]	new[41]	_	_
4-22	633-636	and	_	_	_	_
4-23	637-640	has	_	_	_	_
4-24	641-642	a	quantity[42]	new[42]	_	_
4-25	643-650	limited	quantity[42]	new[42]	_	_
4-26	651-657	supply	quantity[42]	new[42]	_	_
4-27	658-659	.	_	_	_	_

#Text=The main advantage of a xenograft is its abundant supply and no need for secondary surgery , but poor implantation results and problems of infection from donors are critical issues .
5-1	660-663	The	abstract[43]	new[43]	coref	5-8[46_43]
5-2	664-668	main	abstract[43]	new[43]	_	_
5-3	669-678	advantage	abstract[43]	new[43]	_	_
5-4	679-681	of	abstract[43]	new[43]	_	_
5-5	682-683	a	abstract[43]|object[44]	new[43]|new[44]	ana	5-8[0_44]
5-6	684-693	xenograft	abstract[43]|object[44]	new[43]|new[44]	_	_
5-7	694-696	is	_	_	_	_
5-8	697-700	its	object|abstract[46]	giv|giv[46]	_	_
5-9	701-709	abundant	abstract[46]	giv[46]	_	_
5-10	710-716	supply	abstract[46]	giv[46]	_	_
5-11	717-720	and	abstract[46]	giv[46]	_	_
5-12	721-723	no	abstract[46]|abstract[47]	giv[46]|new[47]	coref	18-26[184_47]
5-13	724-728	need	abstract[46]|abstract[47]	giv[46]|new[47]	_	_
5-14	729-732	for	abstract[46]|abstract[47]	giv[46]|new[47]	_	_
5-15	733-742	secondary	abstract[46]|abstract[47]|event[48]	giv[46]|new[47]|giv[48]	_	_
5-16	743-750	surgery	abstract[46]|abstract[47]|event[48]	giv[46]|new[47]|giv[48]	_	_
5-17	751-752	,	abstract[46]	giv[46]	_	_
5-18	753-756	but	abstract[46]	giv[46]	_	_
5-19	757-761	poor	abstract[46]|abstract[50]	giv[46]|giv[50]	_	_
5-20	762-774	implantation	abstract[46]|event|abstract[50]	giv[46]|giv|giv[50]	_	_
5-21	775-782	results	abstract[46]|abstract[50]	giv[46]|giv[50]	_	_
5-22	783-786	and	abstract[46]|abstract[50]	giv[46]|giv[50]	_	_
5-23	787-795	problems	abstract[46]|abstract[50]|abstract[51]	giv[46]|giv[50]|new[51]	coref	5-29[54_51]
5-24	796-798	of	abstract[46]|abstract[50]|abstract[51]	giv[46]|giv[50]|new[51]	_	_
5-25	799-808	infection	abstract[46]|abstract[50]|abstract[51]|event[52]	giv[46]|giv[50]|new[51]|new[52]	_	_
5-26	809-813	from	abstract[46]|abstract[50]|abstract[51]|event[52]	giv[46]|giv[50]|new[51]|new[52]	_	_
5-27	814-820	donors	abstract[46]|abstract[50]|abstract[51]|event[52]|person	giv[46]|giv[50]|new[51]|new[52]|new	_	_
5-28	821-824	are	abstract[46]	giv[46]	_	_
5-29	825-833	critical	abstract[46]|abstract[54]	giv[46]|giv[54]	_	_
5-30	834-840	issues	abstract[46]|abstract[54]	giv[46]|giv[54]	_	_
5-31	841-842	.	_	_	_	_

#Text=Besides , the neo-tissue generated within the interstitial spaces of these grafts is often different from the native tissue and requires large remodeling time for the complete biological and biomechanical integration with surrounding tissues .
6-1	843-850	Besides	_	_	_	_
6-2	851-852	,	_	_	_	_
6-3	853-856	the	substance[55]	new[55]	_	_
6-4	857-867	neo-tissue	substance[55]	new[55]	_	_
6-5	868-877	generated	_	_	_	_
6-6	878-884	within	_	_	_	_
6-7	885-888	the	abstract[56]	new[56]	_	_
6-8	889-901	interstitial	abstract[56]	new[56]	_	_
6-9	902-908	spaces	abstract[56]	new[56]	_	_
6-10	909-911	of	abstract[56]	new[56]	_	_
6-11	912-917	these	abstract[56]|object[57]	new[56]|new[57]	_	_
6-12	918-924	grafts	abstract[56]|object[57]	new[56]|new[57]	_	_
6-13	925-927	is	_	_	_	_
6-14	928-933	often	_	_	_	_
6-15	934-943	different	_	_	_	_
6-16	944-948	from	_	_	_	_
6-17	949-952	the	object[58]	giv[58]	coref	8-1[0_58]
6-18	953-959	native	object[58]	giv[58]	_	_
6-19	960-966	tissue	object[58]	giv[58]	_	_
6-20	967-970	and	_	_	_	_
6-21	971-979	requires	_	_	_	_
6-22	980-985	large	abstract[60]	new[60]	_	_
6-23	986-996	remodeling	event|abstract[60]	new|new[60]	_	_
6-24	997-1001	time	abstract[60]	new[60]	_	_
6-25	1002-1005	for	_	_	_	_
6-26	1006-1009	the	abstract[61]	new[61]	coref	11-25[106_61]
6-27	1010-1018	complete	abstract[61]	new[61]	_	_
6-28	1019-1029	biological	abstract[61]	new[61]	_	_
6-29	1030-1033	and	abstract[61]	new[61]	_	_
6-30	1034-1047	biomechanical	abstract[61]	new[61]	_	_
6-31	1048-1059	integration	abstract[61]	new[61]	_	_
6-32	1060-1064	with	abstract[61]	new[61]	_	_
6-33	1065-1076	surrounding	abstract[61]|object[62]	new[61]|giv[62]	coref	7-11[66_62]
6-34	1077-1084	tissues	abstract[61]|object[62]	new[61]|giv[62]	_	_
6-35	1085-1086	.	_	_	_	_

#Text=For these reasons , the development of novel solutions for tissues and organs bioengineering is extremely demanding in the medical field .
7-1	1087-1090	For	_	_	_	_
7-2	1091-1096	these	abstract[63]	giv[63]	_	_
7-3	1097-1104	reasons	abstract[63]	giv[63]	_	_
7-4	1105-1106	,	_	_	_	_
7-5	1107-1110	the	abstract[64]	new[64]	_	_
7-6	1111-1122	development	abstract[64]	new[64]	_	_
7-7	1123-1125	of	abstract[64]	new[64]	_	_
7-8	1126-1131	novel	abstract[64]|abstract[65]	new[64]|new[65]	_	_
7-9	1132-1141	solutions	abstract[64]|abstract[65]	new[64]|new[65]	_	_
7-10	1142-1145	for	abstract[64]|abstract[65]	new[64]|new[65]	_	_
7-11	1146-1153	tissues	abstract[64]|abstract[65]|object[66]	new[64]|new[65]|giv[66]	_	_
7-12	1154-1157	and	abstract[64]|abstract[65]|object[66]	new[64]|new[65]|giv[66]	_	_
7-13	1158-1164	organs	abstract[64]|abstract[65]|object[66]|object	new[64]|new[65]|giv[66]|giv	coref	8-38
7-14	1165-1179	bioengineering	abstract[64]|abstract[65]|object[66]|person	new[64]|new[65]|giv[66]|new	_	_
7-15	1180-1182	is	_	_	_	_
7-16	1183-1192	extremely	_	_	_	_
7-17	1193-1202	demanding	_	_	_	_
7-18	1203-1205	in	_	_	_	_
7-19	1206-1209	the	abstract[69]	new[69]	_	_
7-20	1210-1217	medical	abstract[69]	new[69]	_	_
7-21	1218-1223	field	abstract[69]	new[69]	_	_
7-22	1224-1225	.	_	_	_	_

#Text=Tissue engineering ( TE ) , an important biomedical engineering field , aims to solve this important challenge by combining scaffolds and bioactive molecules for the artificial reconstruction of functional , three-dimensional ( 3D ) tissues and organs .
8-1	1226-1232	Tissue	object|abstract[71]	giv|giv[71]	appos|coref|appos|coref	8-4[0_71]|9-15|8-4[0_71]|9-15
8-2	1233-1244	engineering	abstract[71]	giv[71]	_	_
8-3	1245-1246	(	_	_	_	_
8-4	1247-1249	TE	abstract	giv	appos	8-7[73_0]
8-5	1250-1251	)	_	_	_	_
8-6	1252-1253	,	_	_	_	_
8-7	1254-1256	an	abstract[73]	giv[73]	coref	20-23[213_73]
8-8	1257-1266	important	abstract[73]	giv[73]	_	_
8-9	1267-1277	biomedical	abstract[73]	giv[73]	_	_
8-10	1278-1289	engineering	abstract[73]	giv[73]	_	_
8-11	1290-1295	field	abstract[73]	giv[73]	_	_
8-12	1296-1297	,	_	_	_	_
8-13	1298-1302	aims	_	_	_	_
8-14	1303-1305	to	_	_	_	_
8-15	1306-1311	solve	_	_	_	_
8-16	1312-1316	this	abstract[74]	new[74]	_	_
8-17	1317-1326	important	abstract[74]	new[74]	_	_
8-18	1327-1336	challenge	abstract[74]	new[74]	_	_
8-19	1337-1339	by	_	_	_	_
8-20	1340-1349	combining	_	_	_	_
8-21	1350-1359	scaffolds	object|abstract[76]	giv|giv[76]	coref|coref	9-1[83_0]|9-1[83_0]
8-22	1360-1363	and	abstract[76]	giv[76]	_	_
8-23	1364-1373	bioactive	abstract[76]|substance[77]	giv[76]|new[77]	coref	10-21[94_77]
8-24	1374-1383	molecules	abstract[76]|substance[77]	giv[76]|new[77]	_	_
8-25	1384-1387	for	_	_	_	_
8-26	1388-1391	the	abstract[78]	new[78]	_	_
8-27	1392-1402	artificial	abstract[78]	new[78]	_	_
8-28	1403-1417	reconstruction	abstract[78]	new[78]	_	_
8-29	1418-1420	of	abstract[78]	new[78]	_	_
8-30	1421-1431	functional	abstract[78]|object[80]|object[81]	new[78]|new[80]|new[81]	coref|coref|coref|coref	11-19[104_80]|14-5[126_81]|11-19[104_80]|14-5[126_81]
8-31	1432-1433	,	abstract[78]|object[80]|object[81]	new[78]|new[80]|new[81]	_	_
8-32	1434-1451	three-dimensional	abstract[78]|object[80]|object[81]	new[78]|new[80]|new[81]	_	_
8-33	1452-1453	(	abstract[78]|object[80]|object[81]	new[78]|new[80]|new[81]	_	_
8-34	1454-1456	3D	abstract[78]|abstract|object[80]|object[81]	new[78]|new|new[80]|new[81]	coref	13-15
8-35	1457-1458	)	abstract[78]|object[80]|object[81]	new[78]|new[80]|new[81]	_	_
8-36	1459-1466	tissues	abstract[78]|object[80]|object[81]	new[78]|new[80]|new[81]	_	_
8-37	1467-1470	and	abstract[78]|object[81]	new[78]|new[81]	_	_
8-38	1471-1477	organs	abstract[78]|object[81]|object	new[78]|new[81]|giv	coref	14-8
8-39	1478-1479	.	_	_	_	_

#Text=Biomedical scaffolds are porous , implantable biomaterials , shaped to promptly restore the natural tissue anatomy and mechanical functions .
9-1	1480-1490	Biomedical	object[83]	giv[83]	coref	10-1[88_83]
9-2	1491-1500	scaffolds	object[83]	giv[83]	_	_
9-3	1501-1504	are	_	_	_	_
9-4	1505-1511	porous	_	_	_	_
9-5	1512-1513	,	_	_	_	_
9-6	1514-1525	implantable	substance[84]	new[84]	coref	21-9[231_84]
9-7	1526-1538	biomaterials	substance[84]	new[84]	_	_
9-8	1539-1540	,	_	_	_	_
9-9	1541-1547	shaped	_	_	_	_
9-10	1548-1550	to	_	_	_	_
9-11	1551-1559	promptly	_	_	_	_
9-12	1560-1567	restore	_	_	_	_
9-13	1568-1571	the	abstract[86]	new[86]	_	_
9-14	1572-1579	natural	abstract[86]	new[86]	_	_
9-15	1580-1586	tissue	object|abstract[86]	giv|new[86]	coref	11-26
9-16	1587-1594	anatomy	abstract[86]	new[86]	_	_
9-17	1595-1598	and	_	_	_	_
9-18	1599-1609	mechanical	abstract[87]	new[87]	coref	19-23[198_87]
9-19	1610-1619	functions	abstract[87]	new[87]	_	_
9-20	1620-1621	.	_	_	_	_

#Text=The scaffolds must also be capable of controlling foreign body reaction and new-tissue formation by targeted presentation and delivery of key molecules , e. g. , anti-inflammatory , growth factors , and proteins .
10-1	1622-1625	The	object[88]	giv[88]	coref	11-6[0_88]
10-2	1626-1635	scaffolds	object[88]	giv[88]	_	_
10-3	1636-1640	must	_	_	_	_
10-4	1641-1645	also	_	_	_	_
10-5	1646-1648	be	_	_	_	_
10-6	1649-1656	capable	_	_	_	_
10-7	1657-1659	of	_	_	_	_
10-8	1660-1671	controlling	_	_	_	_
10-9	1672-1679	foreign	abstract[90]	new[90]	_	_
10-10	1680-1684	body	organization|abstract[90]	giv|new[90]	coref	14-17[131_0]
10-11	1685-1693	reaction	abstract[90]	new[90]	_	_
10-12	1694-1697	and	_	_	_	_
10-13	1698-1708	new-tissue	abstract[91]	new[91]	_	_
10-14	1709-1718	formation	abstract[91]	new[91]	_	_
10-15	1719-1721	by	_	_	_	_
10-16	1722-1730	targeted	abstract[92]	new[92]	_	_
10-17	1731-1743	presentation	abstract[92]	new[92]	_	_
10-18	1744-1747	and	_	_	_	_
10-19	1748-1756	delivery	abstract[93]	new[93]	_	_
10-20	1757-1759	of	abstract[93]	new[93]	_	_
10-21	1760-1763	key	abstract[93]|substance[94]	new[93]|giv[94]	coref	11-3[99_94]
10-22	1764-1773	molecules	abstract[93]|substance[94]	new[93]|giv[94]	_	_
10-23	1774-1775	,	abstract[93]	new[93]	_	_
10-24	1776-1778	e.	abstract[93]|abstract[95]	new[93]|new[95]	_	_
10-25	1779-1781	g.	abstract[93]|abstract[95]	new[93]|new[95]	_	_
10-26	1782-1783	,	abstract[93]	new[93]	_	_
10-27	1784-1801	anti-inflammatory	abstract[93]	new[93]	_	_
10-28	1802-1803	,	abstract[93]	new[93]	_	_
10-29	1804-1810	growth	abstract[93]|abstract|abstract[97]	new[93]|giv|new[97]	coref|coref|coref|coref	17-26[179_0]|21-11[233_97]|17-26[179_0]|21-11[233_97]
10-30	1811-1818	factors	abstract[93]|abstract[97]	new[93]|new[97]	_	_
10-31	1819-1820	,	abstract[93]	new[93]	_	_
10-32	1821-1824	and	abstract[93]	new[93]	_	_
10-33	1825-1833	proteins	abstract[93]|substance	new[93]|new	_	_
10-34	1834-1835	.	_	_	_	_

#Text=Indeed , these molecules help scaffolds to reduce inflammation , recruit and direct differentiation of stem cells from surrounding tissues and ultimately , promote functional tissue integration in situ .
11-1	1836-1842	Indeed	_	_	_	_
11-2	1843-1844	,	_	_	_	_
11-3	1845-1850	these	substance[99]	giv[99]	coref	18-30[185_99]
11-4	1851-1860	molecules	substance[99]	giv[99]	_	_
11-5	1861-1865	help	_	_	_	_
11-6	1866-1875	scaffolds	object	giv	coref	12-1
11-7	1876-1878	to	_	_	_	_
11-8	1879-1885	reduce	_	_	_	_
11-9	1886-1898	inflammation	abstract	new	_	_
11-10	1899-1900	,	_	_	_	_
11-11	1901-1908	recruit	_	_	_	_
11-12	1909-1912	and	_	_	_	_
11-13	1913-1919	direct	abstract[102]	new[102]	_	_
11-14	1920-1935	differentiation	abstract[102]	new[102]	_	_
11-15	1936-1938	of	abstract[102]	new[102]	_	_
11-16	1939-1943	stem	abstract[102]|object[103]	new[102]|new[103]	coref	13-6[118_103]
11-17	1944-1949	cells	abstract[102]|object[103]	new[102]|new[103]	_	_
11-18	1950-1954	from	abstract[102]|object[103]	new[102]|new[103]	_	_
11-19	1955-1966	surrounding	abstract[102]|object[103]|object[104]	new[102]|new[103]|giv[104]	coref	13-2[117_104]
11-20	1967-1974	tissues	abstract[102]|object[103]|object[104]	new[102]|new[103]|giv[104]	_	_
11-21	1975-1978	and	abstract[102]|object[103]	new[102]|new[103]	_	_
11-22	1979-1989	ultimately	abstract[102]|object[103]	new[102]|new[103]	_	_
11-23	1990-1991	,	_	_	_	_
11-24	1992-1999	promote	_	_	_	_
11-25	2000-2010	functional	abstract[106]	giv[106]	_	_
11-26	2011-2017	tissue	object|abstract[106]	giv|giv[106]	coref	13-20
11-27	2018-2029	integration	abstract[106]	giv[106]	_	_
11-28	2030-2032	in	abstract[106]	giv[106]	_	_
11-29	2033-2037	situ	abstract[106]	giv[106]	_	_
11-30	2038-2039	.	_	_	_	_

#Text=Scaffolds design and fabrication have evolved greatly in the past twenty years due to the large knowledge accumulated on materials design , processing and characterization of cell/scaffold interactions .
12-1	2040-2049	Scaffolds	object|abstract[108]	giv|new[108]	coref|coref|coref|coref	12-20[113_108]|14-11|12-20[113_108]|14-11
12-2	2050-2056	design	abstract[108]	new[108]	_	_
12-3	2057-2060	and	_	_	_	_
12-4	2061-2072	fabrication	abstract	giv	_	_
12-5	2073-2077	have	_	_	_	_
12-6	2078-2085	evolved	_	_	_	_
12-7	2086-2093	greatly	_	_	_	_
12-8	2094-2096	in	_	_	_	_
12-9	2097-2100	the	time[110]	new[110]	_	_
12-10	2101-2105	past	time[110]	new[110]	_	_
12-11	2106-2112	twenty	time[110]	new[110]	_	_
12-12	2113-2118	years	time[110]	new[110]	_	_
12-13	2119-2122	due	_	_	_	_
12-14	2123-2125	to	_	_	_	_
12-15	2126-2129	the	abstract[111]	new[111]	_	_
12-16	2130-2135	large	abstract[111]	new[111]	_	_
12-17	2136-2145	knowledge	abstract[111]	new[111]	_	_
12-18	2146-2157	accumulated	_	_	_	_
12-19	2158-2160	on	_	_	_	_
12-20	2161-2170	materials	substance|abstract[113]	new|giv[113]	coref|coref|coref|coref	16-1[164_0]|20-4[0_113]|16-1[164_0]|20-4[0_113]
12-21	2171-2177	design	abstract[113]	giv[113]	_	_
12-22	2178-2179	,	_	_	_	_
12-23	2180-2190	processing	abstract	new	coref	21-15
12-24	2191-2194	and	_	_	_	_
12-25	2195-2211	characterization	abstract[115]	new[115]	_	_
12-26	2212-2214	of	abstract[115]	new[115]	_	_
12-27	2215-2228	cell/scaffold	abstract[115]|abstract[116]	new[115]|new[116]	_	_
12-28	2229-2241	interactions	abstract[115]|abstract[116]	new[115]|new[116]	_	_
12-29	2242-2243	.	_	_	_	_

#Text=In the natural tissues , cells and extracellular matrix ( ECM ) organize into 3D structures from sub-cellular to tissue level .
13-1	2244-2246	In	_	_	_	_
13-2	2247-2250	the	object[117]	giv[117]	coref	14-5[125_117]
13-3	2251-2258	natural	object[117]	giv[117]	_	_
13-4	2259-2266	tissues	object[117]	giv[117]	_	_
13-5	2267-2268	,	_	_	_	_
13-6	2269-2274	cells	object[118]	giv[118]	coref	14-29[0_118]
13-7	2275-2278	and	object[118]	giv[118]	_	_
13-8	2279-2292	extracellular	object[118]|object[119]	giv[118]|new[119]	coref	18-35[187_119]
13-9	2293-2299	matrix	object[118]|object[119]	giv[118]|new[119]	_	_
13-10	2300-2301	(	_	_	_	_
13-11	2302-2305	ECM	place	new	coref	19-41[203_0]
13-12	2306-2307	)	_	_	_	_
13-13	2308-2316	organize	_	_	_	_
13-14	2317-2321	into	_	_	_	_
13-15	2322-2324	3D	abstract|abstract[122]	giv|new[122]	_	_
13-16	2325-2335	structures	abstract[122]	new[122]	_	_
13-17	2336-2340	from	_	_	_	_
13-18	2341-2353	sub-cellular	_	_	_	_
13-19	2354-2356	to	_	_	_	_
13-20	2357-2363	tissue	object|abstract[124]	giv|new[124]	coref|coref	14-34|14-34
13-21	2364-2369	level	abstract[124]	new[124]	_	_
13-22	2370-2371	.	_	_	_	_

#Text=Consequently , to engineer functional tissues and organs successfully , scaffolds must capture the essence of this cells/ECM organization and must provide a porous structure able to facilitate cells distribution and guide 3D tissue regeneration .
14-1	2372-2384	Consequently	_	_	_	_
14-2	2385-2386	,	_	_	_	_
14-3	2387-2389	to	_	_	_	_
14-4	2390-2398	engineer	_	_	_	_
14-5	2399-2409	functional	object[125]|object[126]	giv[125]|giv[126]	coref|coref	23-23[251_125]|23-23[251_125]
14-6	2410-2417	tissues	object[125]|object[126]	giv[125]|giv[126]	_	_
14-7	2418-2421	and	object[126]	giv[126]	_	_
14-8	2422-2428	organs	object[126]|object	giv[126]|giv	_	_
14-9	2429-2441	successfully	_	_	_	_
14-10	2442-2443	,	_	_	_	_
14-11	2444-2453	scaffolds	object	giv	coref	15-1
14-12	2454-2458	must	_	_	_	_
14-13	2459-2466	capture	_	_	_	_
14-14	2467-2470	the	abstract[129]	new[129]	_	_
14-15	2471-2478	essence	abstract[129]	new[129]	_	_
14-16	2479-2481	of	abstract[129]	new[129]	_	_
14-17	2482-2486	this	abstract[129]|abstract[131]	new[129]|giv[131]	coref	15-44[0_131]
14-18	2487-2496	cells/ECM	abstract[129]|abstract|abstract[131]	new[129]|new|giv[131]	_	_
14-19	2497-2509	organization	abstract[129]|abstract[131]	new[129]|giv[131]	_	_
14-20	2510-2513	and	_	_	_	_
14-21	2514-2518	must	_	_	_	_
14-22	2519-2526	provide	_	_	_	_
14-23	2527-2528	a	abstract[132]	new[132]	ana	16-35[0_132]
14-24	2529-2535	porous	abstract[132]	new[132]	_	_
14-25	2536-2545	structure	abstract[132]	new[132]	_	_
14-26	2546-2550	able	_	_	_	_
14-27	2551-2553	to	_	_	_	_
14-28	2554-2564	facilitate	_	_	_	_
14-29	2565-2570	cells	object|abstract[134]	giv|new[134]	coref|coref	15-35|15-35
14-30	2571-2583	distribution	abstract[134]	new[134]	_	_
14-31	2584-2587	and	_	_	_	_
14-32	2588-2593	guide	_	_	_	_
14-33	2594-2596	3D	abstract[136]	new[136]	_	_
14-34	2597-2603	tissue	object|abstract[136]	giv|new[136]	coref	16-29[171_0]
14-35	2604-2616	regeneration	abstract[136]	new[136]	_	_
14-36	2617-2618	.	_	_	_	_

#Text=Scaffolds pore size and shape , pore wall morphology , porosity , surface area and pore interconnectivity , are probably the most important architectural parameters , as they have been shown to directly impact cells migration and colonization , new ECM biosynthesis and organization , oxygen and nutrients transport to cells , as well as metabolic wastes removal in the whole cell/scaffold construct .
15-1	2619-2628	Scaffolds	object|abstract[139]	giv|new[139]	coref|coref	18-10[181_0]|18-10[181_0]
15-2	2629-2633	pore	abstract|abstract[139]	new|new[139]	coref	15-7
15-3	2634-2638	size	abstract[139]	new[139]	_	_
15-4	2639-2642	and	_	_	_	_
15-5	2643-2648	shape	abstract	new	_	_
15-6	2649-2650	,	_	_	_	_
15-7	2651-2655	pore	object|person[143]	giv|new[143]	coref|coref	15-16|15-16
15-8	2656-2660	wall	object|person[143]	new|new[143]	_	_
15-9	2661-2671	morphology	person[143]	new[143]	_	_
15-10	2672-2673	,	_	_	_	_
15-11	2674-2682	porosity	abstract	new	_	_
15-12	2683-2684	,	_	_	_	_
15-13	2685-2692	surface	place|abstract[146]	new|new[146]	_	_
15-14	2693-2697	area	abstract[146]	new[146]	_	_
15-15	2698-2701	and	_	_	_	_
15-16	2702-2706	pore	abstract|abstract[148]	giv|new[148]	coref|coref	15-20[149_148]|15-20[149_148]
15-17	2707-2724	interconnectivity	abstract[148]	new[148]	_	_
15-18	2725-2726	,	_	_	_	_
15-19	2727-2730	are	_	_	_	_
15-20	2731-2739	probably	abstract[149]	giv[149]	ana	15-28[0_149]
15-21	2740-2743	the	abstract[149]	giv[149]	_	_
15-22	2744-2748	most	abstract[149]	giv[149]	_	_
15-23	2749-2758	important	abstract[149]	giv[149]	_	_
15-24	2759-2772	architectural	abstract[149]	giv[149]	_	_
15-25	2773-2783	parameters	abstract[149]	giv[149]	_	_
15-26	2784-2785	,	_	_	_	_
15-27	2786-2788	as	_	_	_	_
15-28	2789-2793	they	object	giv	coref	22-10
15-29	2794-2798	have	_	_	_	_
15-30	2799-2803	been	_	_	_	_
15-31	2804-2809	shown	_	_	_	_
15-32	2810-2812	to	_	_	_	_
15-33	2813-2821	directly	_	_	_	_
15-34	2822-2828	impact	_	_	_	_
15-35	2829-2834	cells	object|abstract[152]	giv|new[152]	coref|coref	15-51|15-51
15-36	2835-2844	migration	abstract[152]	new[152]	_	_
15-37	2845-2848	and	_	_	_	_
15-38	2849-2861	colonization	event	new	_	_
15-39	2862-2863	,	_	_	_	_
15-40	2864-2867	new	abstract[154]	new[154]	coref	19-38[202_154]
15-41	2868-2871	ECM	abstract[154]	new[154]	_	_
15-42	2872-2884	biosynthesis	abstract[154]	new[154]	_	_
15-43	2885-2888	and	_	_	_	_
15-44	2889-2901	organization	abstract	giv	_	_
15-45	2902-2903	,	_	_	_	_
15-46	2904-2910	oxygen	substance	new	_	_
15-47	2911-2914	and	_	_	_	_
15-48	2915-2924	nutrients	substance|abstract[158]	new|new[158]	_	_
15-49	2925-2934	transport	abstract[158]	new[158]	_	_
15-50	2935-2937	to	abstract[158]	new[158]	_	_
15-51	2938-2943	cells	abstract[158]|object	new[158]|giv	coref	18-42
15-52	2944-2945	,	_	_	_	_
15-53	2946-2948	as	_	_	_	_
15-54	2949-2953	well	_	_	_	_
15-55	2954-2956	as	_	_	_	_
15-56	2957-2966	metabolic	abstract[161]	new[161]	_	_
15-57	2967-2973	wastes	substance|abstract[161]	new|new[161]	_	_
15-58	2974-2981	removal	abstract[161]	new[161]	_	_
15-59	2982-2984	in	abstract[161]	new[161]	_	_
15-60	2985-2988	the	abstract[161]|abstract[162]	new[161]|new[162]	_	_
15-61	2989-2994	whole	abstract[161]|abstract[162]	new[161]|new[162]	_	_
15-62	2995-3008	cell/scaffold	abstract[161]|abstract[162]	new[161]|new[162]	_	_
15-63	3009-3018	construct	abstract[161]|abstract[162]	new[161]|new[162]	_	_
15-64	3019-3020	.	_	_	_	_

#Text=The scaffold material must be selected and/or designed with a degradation and resorption rate such that scaffold strength is retained until the tissue-engineered transplant is fully remodeled by the host tissue and can assume its own structural role .
16-1	3021-3024	The	substance[164]	giv[164]	_	_
16-2	3025-3033	scaffold	object|substance[164]	new|giv[164]	coref	16-17
16-3	3034-3042	material	substance[164]	giv[164]	_	_
16-4	3043-3047	must	_	_	_	_
16-5	3048-3050	be	_	_	_	_
16-6	3051-3059	selected	_	_	_	_
16-7	3060-3066	and/or	_	_	_	_
16-8	3067-3075	designed	_	_	_	_
16-9	3076-3080	with	_	_	_	_
16-10	3081-3082	a	abstract[165]	new[165]	_	_
16-11	3083-3094	degradation	abstract[165]	new[165]	_	_
16-12	3095-3098	and	_	_	_	_
16-13	3099-3109	resorption	abstract|abstract[167]	new|new[167]	_	_
16-14	3110-3114	rate	abstract[167]	new[167]	_	_
16-15	3115-3119	such	_	_	_	_
16-16	3120-3124	that	_	_	_	_
16-17	3125-3133	scaffold	object|abstract[169]	giv|new[169]	coref|coref	20-25|20-25
16-18	3134-3142	strength	abstract[169]	new[169]	_	_
16-19	3143-3145	is	_	_	_	_
16-20	3146-3154	retained	_	_	_	_
16-21	3155-3160	until	_	_	_	_
16-22	3161-3164	the	object[170]	new[170]	_	_
16-23	3165-3182	tissue-engineered	object[170]	new[170]	_	_
16-24	3183-3193	transplant	object[170]	new[170]	_	_
16-25	3194-3196	is	_	_	_	_
16-26	3197-3202	fully	_	_	_	_
16-27	3203-3212	remodeled	_	_	_	_
16-28	3213-3215	by	_	_	_	_
16-29	3216-3219	the	object[171]	giv[171]	coref	17-26[0_171]
16-30	3220-3224	host	object[171]	giv[171]	_	_
16-31	3225-3231	tissue	object[171]	giv[171]	_	_
16-32	3232-3235	and	_	_	_	_
16-33	3236-3239	can	_	_	_	_
16-34	3240-3246	assume	_	_	_	_
16-35	3247-3250	its	abstract|abstract[173]	giv|new[173]	coref|coref	20-29[217_0]|20-29[217_0]
16-36	3251-3254	own	abstract[173]	new[173]	_	_
16-37	3255-3265	structural	abstract[173]	new[173]	_	_
16-38	3266-3270	role	abstract[173]	new[173]	_	_
16-39	3271-3272	.	_	_	_	_

#Text=More importantly , controlling mechanical properties at cellular and sub-cellular levels is important to emulate as closely as possible the in vivo cell behavior and tissue growth .
17-1	3273-3277	More	_	_	_	_
17-2	3278-3289	importantly	_	_	_	_
17-3	3290-3291	,	_	_	_	_
17-4	3292-3303	controlling	_	_	_	_
17-5	3304-3314	mechanical	abstract[174]	new[174]	coref	18-4[180_174]
17-6	3315-3325	properties	abstract[174]	new[174]	_	_
17-7	3326-3328	at	_	_	_	_
17-8	3329-3337	cellular	abstract[175]	new[175]	_	_
17-9	3338-3341	and	abstract[175]	new[175]	_	_
17-10	3342-3354	sub-cellular	abstract[175]	new[175]	_	_
17-11	3355-3361	levels	abstract[175]	new[175]	_	_
17-12	3362-3364	is	_	_	_	_
17-13	3365-3374	important	_	_	_	_
17-14	3375-3377	to	_	_	_	_
17-15	3378-3385	emulate	_	_	_	_
17-16	3386-3388	as	_	_	_	_
17-17	3389-3396	closely	_	_	_	_
17-18	3397-3399	as	_	_	_	_
17-19	3400-3408	possible	_	_	_	_
17-20	3409-3412	the	abstract[177]	new[177]	coref	18-42[189_177]
17-21	3413-3415	in	abstract[177]	new[177]	_	_
17-22	3416-3420	vivo	abstract[177]	new[177]	_	_
17-23	3421-3425	cell	place|abstract[177]	new|new[177]	_	_
17-24	3426-3434	behavior	abstract[177]	new[177]	_	_
17-25	3435-3438	and	_	_	_	_
17-26	3439-3445	tissue	object|abstract[179]	giv|giv[179]	coref|coref|coref|coref	19-48|19-45[205_179]|19-48|19-45[205_179]
17-27	3446-3452	growth	abstract[179]	giv[179]	_	_
17-28	3453-3454	.	_	_	_	_

#Text=Nevertheless , controlling the morphological and biomechanical properties of porous scaffolds is not enough for the success of scaffolds-based therapies , as there is also the need to load matricellular and soluble molecules inside scaffolds ’ matrix as biochemical regulators of cells behavior .
18-1	3455-3467	Nevertheless	_	_	_	_
18-2	3468-3469	,	_	_	_	_
18-3	3470-3481	controlling	_	_	_	_
18-4	3482-3485	the	abstract[180]	giv[180]	coref	23-36[254_180]
18-5	3486-3499	morphological	abstract[180]	giv[180]	_	_
18-6	3500-3503	and	abstract[180]	giv[180]	_	_
18-7	3504-3517	biomechanical	abstract[180]	giv[180]	_	_
18-8	3518-3528	properties	abstract[180]	giv[180]	_	_
18-9	3529-3531	of	abstract[180]	giv[180]	_	_
18-10	3532-3538	porous	abstract[180]|object[181]	giv[180]|giv[181]	coref	18-35[186_181]
18-11	3539-3548	scaffolds	abstract[180]|object[181]	giv[180]|giv[181]	_	_
18-12	3549-3551	is	_	_	_	_
18-13	3552-3555	not	_	_	_	_
18-14	3556-3562	enough	_	_	_	_
18-15	3563-3566	for	_	_	_	_
18-16	3567-3570	the	abstract[182]	new[182]	_	_
18-17	3571-3578	success	abstract[182]	new[182]	_	_
18-18	3579-3581	of	abstract[182]	new[182]	_	_
18-19	3582-3597	scaffolds-based	abstract[182]|abstract[183]	new[182]|new[183]	_	_
18-20	3598-3607	therapies	abstract[182]|abstract[183]	new[182]|new[183]	_	_
18-21	3608-3609	,	_	_	_	_
18-22	3610-3612	as	_	_	_	_
18-23	3613-3618	there	_	_	_	_
18-24	3619-3621	is	_	_	_	_
18-25	3622-3626	also	_	_	_	_
18-26	3627-3630	the	abstract[184]	giv[184]	_	_
18-27	3631-3635	need	abstract[184]	giv[184]	_	_
18-28	3636-3638	to	_	_	_	_
18-29	3639-3643	load	_	_	_	_
18-30	3644-3657	matricellular	substance[185]	giv[185]	_	_
18-31	3658-3661	and	substance[185]	giv[185]	_	_
18-32	3662-3669	soluble	substance[185]	giv[185]	_	_
18-33	3670-3679	molecules	substance[185]	giv[185]	_	_
18-34	3680-3686	inside	_	_	_	_
18-35	3687-3696	scaffolds	object[186]|object[187]	giv[186]|giv[187]	coref|coref	19-7[191_186]|19-7[191_186]
18-36	3697-3698	’	object[186]|object[187]	giv[186]|giv[187]	_	_
18-37	3699-3705	matrix	object[187]	giv[187]	_	_
18-38	3706-3708	as	object[187]	giv[187]	_	_
18-39	3709-3720	biochemical	object[187]	giv[187]	_	_
18-40	3721-3731	regulators	object[187]	giv[187]	_	_
18-41	3732-3734	of	object[187]	giv[187]	_	_
18-42	3735-3740	cells	object[187]|object|abstract[189]	giv[187]|giv|giv[189]	ana|coref|ana|coref	19-3[0_189]|19-23[197_0]|19-3[0_189]|19-23[197_0]
18-43	3741-3749	behavior	object[187]|abstract[189]	giv[187]|giv[189]	_	_
18-44	3750-3751	.	_	_	_	_

#Text=Indeed , it is reported that porous scaffolds releasing biochemical signals following a precise dose and time intervals to target sites stimulate cells ’ functions ( e. g. , adhesion , proliferation and migration ) , promote the biosynthesis of new ECM and , ultimately , guide tissue growth , morphogenesis and vascularization .
19-1	3752-3758	Indeed	_	_	_	_
19-2	3759-3760	,	_	_	_	_
19-3	3761-3763	it	abstract	giv	_	_
19-4	3764-3766	is	_	_	_	_
19-5	3767-3775	reported	_	_	_	_
19-6	3776-3780	that	_	_	_	_
19-7	3781-3787	porous	object[191]	giv[191]	coref	20-2[208_191]
19-8	3788-3797	scaffolds	object[191]	giv[191]	_	_
19-9	3798-3807	releasing	_	_	_	_
19-10	3808-3819	biochemical	abstract[192]	new[192]	_	_
19-11	3820-3827	signals	abstract[192]	new[192]	_	_
19-12	3828-3837	following	_	_	_	_
19-13	3838-3839	a	quantity[193]	new[193]	_	_
19-14	3840-3847	precise	quantity[193]	new[193]	_	_
19-15	3848-3852	dose	quantity[193]	new[193]	_	_
19-16	3853-3856	and	_	_	_	_
19-17	3857-3861	time	time|time[195]	new|new[195]	_	_
19-18	3862-3871	intervals	time[195]	new[195]	_	_
19-19	3872-3874	to	_	_	_	_
19-20	3875-3881	target	_	_	_	_
19-21	3882-3887	sites	place	new	_	_
19-22	3888-3897	stimulate	_	_	_	_
19-23	3898-3903	cells	object[197]|event[198]	giv[197]|giv[198]	appos|coref|appos|coref	19-30[0_198]|20-46[221_197]|19-30[0_198]|20-46[221_197]
19-24	3904-3905	’	object[197]|event[198]	giv[197]|giv[198]	_	_
19-25	3906-3915	functions	event[198]	giv[198]	_	_
19-26	3916-3917	(	_	_	_	_
19-27	3918-3920	e.	_	_	_	_
19-28	3921-3923	g.	_	_	_	_
19-29	3924-3925	,	_	_	_	_
19-30	3926-3934	adhesion	abstract	giv	appos	19-32
19-31	3935-3936	,	_	_	_	_
19-32	3937-3950	proliferation	event	giv	appos	19-34
19-33	3951-3954	and	_	_	_	_
19-34	3955-3964	migration	event	giv	_	_
19-35	3965-3966	)	_	_	_	_
19-36	3967-3968	,	_	_	_	_
19-37	3969-3976	promote	_	_	_	_
19-38	3977-3980	the	abstract[202]	giv[202]	_	_
19-39	3981-3993	biosynthesis	abstract[202]	giv[202]	_	_
19-40	3994-3996	of	abstract[202]	giv[202]	_	_
19-41	3997-4000	new	abstract[202]|place[203]	giv[202]|giv[203]	coref	20-30[0_203]
19-42	4001-4004	ECM	abstract[202]|place[203]	giv[202]|giv[203]	_	_
19-43	4005-4008	and	abstract[202]	giv[202]	_	_
19-44	4009-4010	,	abstract[202]	giv[202]	_	_
19-45	4011-4021	ultimately	abstract[202]|abstract[205]	giv[202]|giv[205]	coref	20-46[222_205]
19-46	4022-4023	,	abstract[202]|abstract[205]	giv[202]|giv[205]	_	_
19-47	4024-4029	guide	abstract[202]|abstract[205]	giv[202]|giv[205]	_	_
19-48	4030-4036	tissue	abstract[202]|object|abstract[205]	giv[202]|giv|giv[205]	coref	20-50
19-49	4037-4043	growth	abstract[202]|abstract[205]	giv[202]|giv[205]	_	_
19-50	4044-4045	,	abstract[202]	giv[202]	_	_
19-51	4046-4059	morphogenesis	abstract[202]|abstract	giv[202]|new	coref	20-50[224_0]
19-52	4060-4063	and	abstract[202]	giv[202]	_	_
19-53	4064-4079	vascularization	abstract[202]|abstract	giv[202]|new	_	_
19-54	4080-4081	.	_	_	_	_

#Text=Increasing scaffolds ’ design complexity is therefore extremely demanding and scientists face some important challenges , such as : ( 1 ) engineering of scaffold microarchitecture to mimic the ECM structure , ( 2 ) imprinting topological and biochemical patterns inside scaffolds pores to guide cells ’ growth and tissue morphogenesis , and ( 3 ) developing automated processes for the precise and reliable control of scaffolds ’ features and geometry .
20-1	4082-4092	Increasing	_	_	_	_
20-2	4093-4102	scaffolds	object[208]|abstract[210]	giv[208]|new[210]	coref|coref	20-42[0_208]|20-42[0_208]
20-3	4103-4104	’	object[208]|abstract[210]	giv[208]|new[210]	_	_
20-4	4105-4111	design	abstract|abstract[210]	giv|new[210]	_	_
20-5	4112-4122	complexity	abstract[210]	new[210]	_	_
20-6	4123-4125	is	_	_	_	_
20-7	4126-4135	therefore	_	_	_	_
20-8	4136-4145	extremely	_	_	_	_
20-9	4146-4155	demanding	_	_	_	_
20-10	4156-4159	and	_	_	_	_
20-11	4160-4170	scientists	person	new	_	_
20-12	4171-4175	face	_	_	_	_
20-13	4176-4180	some	abstract[212]	new[212]	_	_
20-14	4181-4190	important	abstract[212]	new[212]	_	_
20-15	4191-4201	challenges	abstract[212]	new[212]	_	_
20-16	4202-4203	,	abstract[212]	new[212]	_	_
20-17	4204-4208	such	abstract[212]	new[212]	_	_
20-18	4209-4211	as	abstract[212]	new[212]	_	_
20-19	4212-4213	:	abstract[212]	new[212]	_	_
20-20	4214-4215	(	abstract[212]	new[212]	_	_
20-21	4216-4217	1	abstract[212]	new[212]	_	_
20-22	4218-4219	)	abstract[212]	new[212]	_	_
20-23	4220-4231	engineering	abstract[212]|abstract[213]	new[212]|giv[213]	_	_
20-24	4232-4234	of	abstract[212]|abstract[213]	new[212]|giv[213]	_	_
20-25	4235-4243	scaffold	abstract[212]|abstract[213]|object|object[215]	new[212]|giv[213]|giv|new[215]	_	_
20-26	4244-4261	microarchitecture	abstract[212]|abstract[213]|object[215]	new[212]|giv[213]|new[215]	_	_
20-27	4262-4264	to	_	_	_	_
20-28	4265-4270	mimic	_	_	_	_
20-29	4271-4274	the	abstract[217]	giv[217]	_	_
20-30	4275-4278	ECM	place|abstract[217]	giv|giv[217]	coref	23-18[250_0]
20-31	4279-4288	structure	abstract[217]	giv[217]	_	_
20-32	4289-4290	,	abstract[217]	giv[217]	_	_
20-33	4291-4292	(	abstract[217]	giv[217]	_	_
20-34	4293-4294	2	abstract[217]	giv[217]	_	_
20-35	4295-4296	)	abstract[217]	giv[217]	_	_
20-36	4297-4307	imprinting	_	_	_	_
20-37	4308-4319	topological	abstract[218]	new[218]	_	_
20-38	4320-4323	and	abstract[218]	new[218]	_	_
20-39	4324-4335	biochemical	abstract[218]	new[218]	_	_
20-40	4336-4344	patterns	abstract[218]	new[218]	_	_
20-41	4345-4351	inside	abstract[218]	new[218]	_	_
20-42	4352-4361	scaffolds	abstract[218]|object|object[220]	new[218]|giv|new[220]	coref|coref	20-67[227_0]|20-67[227_0]
20-43	4362-4367	pores	abstract[218]|object[220]	new[218]|new[220]	_	_
20-44	4368-4370	to	_	_	_	_
20-45	4371-4376	guide	_	_	_	_
20-46	4377-4382	cells	object[221]|abstract[222]	giv[221]|giv[222]	coref|coref	21-11[0_222]|21-11[0_222]
20-47	4383-4384	’	object[221]|abstract[222]	giv[221]|giv[222]	_	_
20-48	4385-4391	growth	abstract[222]	giv[222]	_	_
20-49	4392-4395	and	_	_	_	_
20-50	4396-4402	tissue	object|abstract[224]	giv|giv[224]	_	_
20-51	4403-4416	morphogenesis	abstract[224]	giv[224]	_	_
20-52	4417-4418	,	_	_	_	_
20-53	4419-4422	and	_	_	_	_
20-54	4423-4424	(	_	_	_	_
20-55	4425-4426	3	_	_	_	_
20-56	4427-4428	)	_	_	_	_
20-57	4429-4439	developing	_	_	_	_
20-58	4440-4449	automated	abstract[225]	new[225]	_	_
20-59	4450-4459	processes	abstract[225]	new[225]	_	_
20-60	4460-4463	for	abstract[225]	new[225]	_	_
20-61	4464-4467	the	abstract[225]|abstract[226]	new[225]|new[226]	_	_
20-62	4468-4475	precise	abstract[225]|abstract[226]	new[225]|new[226]	_	_
20-63	4476-4479	and	abstract[225]|abstract[226]	new[225]|new[226]	_	_
20-64	4480-4488	reliable	abstract[225]|abstract[226]	new[225]|new[226]	_	_
20-65	4489-4496	control	abstract[225]|abstract[226]	new[225]|new[226]	_	_
20-66	4497-4499	of	abstract[225]|abstract[226]	new[225]|new[226]	_	_
20-67	4500-4509	scaffolds	abstract[225]|abstract[226]|object[227]|abstract[228]	new[225]|new[226]|giv[227]|new[228]	coref|coref	21-1[230_227]|21-1[230_227]
20-68	4510-4511	’	abstract[225]|abstract[226]|object[227]|abstract[228]	new[225]|new[226]|giv[227]|new[228]	_	_
20-69	4512-4520	features	abstract[225]|abstract[226]|abstract[228]	new[225]|new[226]|new[228]	_	_
20-70	4521-4524	and	abstract[225]|abstract[226]	new[225]|new[226]	_	_
20-71	4525-4533	geometry	abstract[225]|abstract[226]|abstract	new[225]|new[226]|new	_	_
20-72	4534-4535	.	_	_	_	_

#Text=Porous bioactive scaffolds can be fabricated by combining biomaterials and growth factors through different processing techniques .
21-1	4536-4542	Porous	object[230]	giv[230]	coref	23-9[0_230]
21-2	4543-4552	bioactive	object[230]	giv[230]	_	_
21-3	4553-4562	scaffolds	object[230]	giv[230]	_	_
21-4	4563-4566	can	_	_	_	_
21-5	4567-4569	be	_	_	_	_
21-6	4570-4580	fabricated	_	_	_	_
21-7	4581-4583	by	_	_	_	_
21-8	4584-4593	combining	_	_	_	_
21-9	4594-4606	biomaterials	substance[231]	giv[231]	_	_
21-10	4607-4610	and	substance[231]	giv[231]	_	_
21-11	4611-4617	growth	substance[231]|abstract|substance[233]	giv[231]|giv|giv[233]	_	_
21-12	4618-4625	factors	substance[231]|substance[233]	giv[231]|giv[233]	_	_
21-13	4626-4633	through	_	_	_	_
21-14	4634-4643	different	abstract[235]	new[235]	_	_
21-15	4644-4654	processing	abstract|abstract[235]	giv|new[235]	_	_
21-16	4655-4665	techniques	abstract[235]	new[235]	_	_
21-17	4666-4667	.	_	_	_	_

#Text=This review focuses the attention on modular approaches where samples are built by the “ bottom-up ” assembly of smaller units or “ modules ” , each one specifically designed for distinct tasks .
22-1	4668-4672	This	event[236]	new[236]	_	_
22-2	4673-4679	review	event[236]	new[236]	_	_
22-3	4680-4687	focuses	_	_	_	_
22-4	4688-4691	the	abstract[237]	new[237]	_	_
22-5	4692-4701	attention	abstract[237]	new[237]	_	_
22-6	4702-4704	on	abstract[237]	new[237]	_	_
22-7	4705-4712	modular	abstract[237]|abstract[238]	new[237]|new[238]	coref	23-3[0_238]
22-8	4713-4723	approaches	abstract[237]|abstract[238]	new[237]|new[238]	_	_
22-9	4724-4729	where	_	_	_	_
22-10	4730-4737	samples	object	giv	_	_
22-11	4738-4741	are	_	_	_	_
22-12	4742-4747	built	_	_	_	_
22-13	4748-4750	by	_	_	_	_
22-14	4751-4754	the	organization[241]	new[241]	_	_
22-15	4755-4756	“	organization[241]	new[241]	_	_
22-16	4757-4766	bottom-up	abstract|organization[241]	new|new[241]	_	_
22-17	4767-4768	”	organization[241]	new[241]	_	_
22-18	4769-4777	assembly	organization[241]	new[241]	_	_
22-19	4778-4780	of	organization[241]	new[241]	_	_
22-20	4781-4788	smaller	organization[241]|object[242]	new[241]|new[242]	_	_
22-21	4789-4794	units	organization[241]|object[242]	new[241]|new[242]	_	_
22-22	4795-4797	or	organization[241]	new[241]	_	_
22-23	4798-4799	“	organization[241]	new[241]	_	_
22-24	4800-4807	modules	organization[241]|place	new[241]|new	coref	23-31[253_0]
22-25	4808-4809	”	organization[241]	new[241]	_	_
22-26	4810-4811	,	_	_	_	_
22-27	4812-4816	each	object[244]	new[244]	_	_
22-28	4817-4820	one	object[244]	new[244]	_	_
22-29	4821-4833	specifically	_	_	_	_
22-30	4834-4842	designed	_	_	_	_
22-31	4843-4846	for	_	_	_	_
22-32	4847-4855	distinct	abstract[245]	new[245]	_	_
22-33	4856-4861	tasks	abstract[245]	new[245]	_	_
22-34	4862-4863	.	_	_	_	_

#Text=Bottom up approaches have the potential to build scaffolds mimicking the complex molecular and structural microenvironment of the native ECM of every kind of tissues by the proper assembly of micro- and nano-structured modules with well-defined morphological and biochemical properties .
23-1	4864-4870	Bottom	_	_	_	_
23-2	4871-4873	up	_	_	_	_
23-3	4874-4884	approaches	abstract	giv	_	_
23-4	4885-4889	have	_	_	_	_
23-5	4890-4893	the	abstract[247]	new[247]	_	_
23-6	4894-4903	potential	abstract[247]	new[247]	_	_
23-7	4904-4906	to	_	_	_	_
23-8	4907-4912	build	_	_	_	_
23-9	4913-4922	scaffolds	object	giv	_	_
23-10	4923-4932	mimicking	_	_	_	_
23-11	4933-4936	the	abstract[249]	new[249]	_	_
23-12	4937-4944	complex	abstract[249]	new[249]	_	_
23-13	4945-4954	molecular	abstract[249]	new[249]	_	_
23-14	4955-4958	and	abstract[249]	new[249]	_	_
23-15	4959-4969	structural	abstract[249]	new[249]	_	_
23-16	4970-4986	microenvironment	abstract[249]	new[249]	_	_
23-17	4987-4989	of	abstract[249]	new[249]	_	_
23-18	4990-4993	the	abstract[249]|place[250]	new[249]|giv[250]	_	_
23-19	4994-5000	native	abstract[249]|place[250]	new[249]|giv[250]	_	_
23-20	5001-5004	ECM	abstract[249]|place[250]	new[249]|giv[250]	_	_
23-21	5005-5007	of	abstract[249]|place[250]	new[249]|giv[250]	_	_
23-22	5008-5013	every	abstract[249]|place[250]	new[249]|giv[250]	_	_
23-23	5014-5018	kind	abstract[249]|place[250]|object[251]	new[249]|giv[250]|giv[251]	_	_
23-24	5019-5021	of	abstract[249]|place[250]|object[251]	new[249]|giv[250]|giv[251]	_	_
23-25	5022-5029	tissues	abstract[249]|place[250]|object[251]	new[249]|giv[250]|giv[251]	_	_
23-26	5030-5032	by	abstract[249]|place[250]	new[249]|giv[250]	_	_
23-27	5033-5036	the	abstract[249]|place[250]|abstract[252]	new[249]|giv[250]|new[252]	_	_
23-28	5037-5043	proper	abstract[249]|place[250]|abstract[252]	new[249]|giv[250]|new[252]	_	_
23-29	5044-5052	assembly	abstract[249]|place[250]|abstract[252]	new[249]|giv[250]|new[252]	_	_
23-30	5053-5055	of	abstract[249]|place[250]|abstract[252]	new[249]|giv[250]|new[252]	_	_
23-31	5056-5062	micro-	abstract[249]|place[250]|abstract[252]|place[253]	new[249]|giv[250]|new[252]|giv[253]	_	_
23-32	5063-5066	and	abstract[249]|place[250]|abstract[252]|place[253]	new[249]|giv[250]|new[252]|giv[253]	_	_
23-33	5067-5082	nano-structured	abstract[249]|place[250]|abstract[252]|place[253]	new[249]|giv[250]|new[252]|giv[253]	_	_
23-34	5083-5090	modules	abstract[249]|place[250]|abstract[252]|place[253]	new[249]|giv[250]|new[252]|giv[253]	_	_
23-35	5091-5095	with	abstract[249]|place[250]|abstract[252]|place[253]	new[249]|giv[250]|new[252]|giv[253]	_	_
23-36	5096-5108	well-defined	abstract[249]|place[250]|abstract[252]|place[253]|abstract[254]	new[249]|giv[250]|new[252]|giv[253]|giv[254]	_	_
23-37	5109-5122	morphological	abstract[249]|place[250]|abstract[252]|place[253]|abstract[254]	new[249]|giv[250]|new[252]|giv[253]|giv[254]	_	_
23-38	5123-5126	and	abstract[249]|place[250]|abstract[252]|place[253]|abstract[254]	new[249]|giv[250]|new[252]|giv[253]|giv[254]	_	_
23-39	5127-5138	biochemical	abstract[249]|place[250]|abstract[252]|place[253]|abstract[254]	new[249]|giv[250]|new[252]|giv[253]|giv[254]	_	_
23-40	5139-5149	properties	abstract[249]|place[250]|abstract[252]|place[253]|abstract[254]	new[249]|giv[250]|new[252]|giv[253]|giv[254]	_	_
23-41	5150-5151	.	_	_	_	_
